Chinese Bulk Aspirin Sales Below Fair Value In U.S. -ITA
This article was originally published in The Tan Sheet
Bulk aspirin imported from the People's Republic of China (PRC) is being, or is likely to be, sold in the U.S. at less than fair value margins ranging up to 144%, the International Trade Administration says in a preliminary determination published in the Federal Register Jan. 3.
You may also be interested in...
The International Trade Commission is instituting an investigation into evidence of possible Chinese aspirin "dumping" onto the U.S. market, the commission announced in the Federal Register June 7. The investigation follows a May 28 petition from bulk aspirin manufacturer Rhodia requesting the "imposition of antidumping duties on imports of bulk aspirin from the People's Republic of China."
Creatine imported from Chinese companies selling the dietary supplement ingredient below fair market prices poses a material threat to U.S. creatine producers, the U.S. International Trade Commission determines in an April preliminary investigation report.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC